Teva UK Limited Welcomes DH Consultation on COPD Strategy

CASTLEFORD, England, April 19, 2010 – Teva UK Limited has welcomed the Department of Health's (DH) consultation
on a Strategy for Services for Chronic Obstructive Pulmonary Disease (COPD).

As well as outlining a strategy for COPD services, the document also
incorporates a strategy for asthma management.
Says Robyn Hughes, Director [...]

What Colour is Your Underwear?

BRADFORD ON AVON, England, April 19, 2010 – Think Training & Development believe that the quality of your
life depends upon the quality of the questions you ask yourself.

Don't worry. They don't actually want to know what colour your
underwear is. Especially if it's grey. The point is, when you saw the
question [...]

Immense Opportunities in Store for the Economically Significant Healthcare Industry in Europe, Finds Frost & Sullivan

LONDON, April 19, 2010 – Healthcare has always been an area of utmost importance. It has
significant economic relevance and has been allocated a higher percent of
gross domestic product (GDP) in many countries compared to most other sectors
such as transport and communication, construction and education. Healthcare
also has a huge impact on employment, for the fact [...]

Wake Up to Nocturia

Studies Reinforce Serious Associated Risk of Nocturia
BARCELONA, Spain, April 19, 2010 – Study results discussed today at the European Association of
Urology (EAU) Congress in Barcelona have reinforced the association between
nocturia and a greater risk of falls and mortality.

In a population-representative study in Japan by Nakagawa et
al , it was concluded [...]

Health Robotics Canada Quickly Becomes Largest American I.V. Robotics Company with 15 Contracts in First 3 Months

BOZEN, Sud-Tirol, Italy, April 19, 2010 – Health Robotics today announced the outstanding results reported by one
of its American partners, Health Robotics Canada Inc. (HRCI) first trimester
of operations since its inception in December 2009. These impressive results
included new contracts in North America for seven i.v.STATION, six i.v.SOFT,
one CytoCare, and one I.V. Room of the [...]

Celtic Pharma Announces Preclinical Findings that XERECEPT(R) Potentiates Significantly the Tumor Inhibition Activity of Avastin(R)

NEW YORK, LONDON and BERMUDA, April 19, 2010 – Celtic Pharmaceutical Holdings L.P. ("Celtic Pharma") today
reported at the AACR 101st Annual Meeting 2010 in Washington, DC the results
from several preclinical studies of XERECEPT(R) in established models for
breast, colon and brain tumors. These animal studies were conducted at Duke
University and the Piedmont Research Center using [...]